Folks here know that just about every day we discuss questions of what molecular marker test to order for lung cancer, how important it is, how it's done, what tissue is needed, and other very timely and practical issues in lung cancer.  These are questions that evolve every few months, as new research emerges with different markers.  

Who is doing this work? People like Dr. Dara Aisner, Co-Director of the Colorado Molecular Correlates Laboratory and Assistant Professor in the Department of Pathology at the University of Colorado.  Yes, that's the same University of Colorado lab that we're always talking about here as representing the absolute leading edge of molecular oncology, one of the very first labs on the planet to do ALK testing and now ROS1 testing, and among the most integral participants in the Lung Cancer Molecular Consortium.  

We're lucky enough to have Dr. Aisner join me on Wednesday, August 22nd at 7 PM Eastern/4 PM Pacific to discuss a broad range of important issues in pathology and molecular diagnostics, ranging from how we get from a biopsy to a marker result, what the current limitations are, how to overcome those barriers, and what the emerging future of molecular oncology looks like.  Sounds very interesting, right?

So join us for this program, co-sponsored with LUNGevity Foundation.  We'll have the audio and video versions of the webinar online, along with the transcript and figures, but you'll want to be there for the live program, with time for your own questions, if you can.  You can also feel free to get a jump on things by suggesting some questions here as a comment.

 Just click here for free registration. I think this webinar will be of great interest to lots of you.